We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Genetic Link to Premenopausal Breast Cancer Discovered

By LabMedica International staff writers
Posted on 03 Jul 2019
Print article
Image: iPLEX Gold is a SNP genotyping assay that runs on Sequenom\'s MassArray mass spectrometer (Photo courtesy of Sequenom).
Image: iPLEX Gold is a SNP genotyping assay that runs on Sequenom\'s MassArray mass spectrometer (Photo courtesy of Sequenom).
Breast cancer is the most common cancer in women, with an estimated one out of every eight women expected to develop it in their lifetimes. While environmental factors like smoking, diet or lack of physical activity can lead to cancer, a person's genes also contribute to the risk of getting the disease.

Scientists have added a new genetic marker to the breast cancer map, helping to expand the list of genetic mutations clinicians can watch for in cancer screenings. Caucasian women carrying the genetic variation compared to women without the variation and in premenopausal women that risk reached as high as 40%. The ability to identify those genes and their variants (called alleles) can be vital to early detection and life-saving treatment.

Medical scientists at the University of Alberta (Edmonton, AB, Canada) examined breast cancer risk in Caucasian women divided into premenopausal and postmenopausal groupings. Because the majority of breast cancers are diagnosed in women over the age of 55, most genetic association studies focus on postmenopausal women. However, inherited forms of cancers, typically related to genetic mutations, are more likely to be more aggressive and be diagnosed earlier in life.

The team examined more than 9,000 women from Alberta for the study, utilizing samples from patients diagnosed with breast cancer and unaffected healthy controls. Genomic DNA was extracted from buffy coat samples using a commercially available Qiagen Tm kit. Genotyping was performed using Sequenom iPLEX Gold platform. Whole genome genotype data was generated using Human Affymetrix SNP 6.0 array (906,600 SNPs) for 348 cases and 348 controls.

The scientists reported that the SNP rs1429142 (C/T, minor allele frequency 18%) showed statistically significant association for the overall breast cancer risk in Stages 1–4 (n = 4,331 cases/4,271 controls), and an elevated risk among premenopausal women (n = 1,503 cases/4,271 controls) in European populations. SNP rs1429142 was associated with premenopausal breast cancer risk in women of African, but not from Chinese ancestry. Fine‐mapping of the locus revealed several potential causal variants, which are present within a single association signal, revealed from the conditional regression analysis.

The authors concluded that they had identified three potential causal variants (rs1366691, rs1429139 and rs7667633) strongly associated with premenopausal breast cancer risk and the variants appear to have enhancer functions, likely regulating the nearby target genes. The study was originally published online on May 14, 2019, in the International Journal of Cancer.

Related Links:
University of Alberta

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.